Techvest 7th Annual Healthcare Conference Presenter Profiles

Business Wire, Nov 4, 2005

NEW YORK -- Techvest 7th Annual Healthcare Conference takes place 07 - 09 Nov. at the New York Palace Hotel in New York City. For in-depth information about the event visit http://www.rodmanandrenshaw.com/index.htm.

Below are profiles from Techvest 7th Annual Healthcare Conference presenters. News releases, web cast advisories, and photos are available at http://home.businesswire.com/portal/site/bwges-techvest-health-05/.

Business Wire is the official news wire service for the Techvest 7th Annual Healthcare Conference.

Company:  Active Biotech AB
Ticker Symbol & Exchange: ACTI.SE    SEK
Investor Relations Contact:   Cecilia Hofvander
Investor Relations Contact Phone: +46 46 19 11 22 or +46 701 89 11 22
Web:      www.activebiotech.com
Date of Presentation: Nov 8

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex(R) for RA.

Company:  Adeza Biomedical
Ticker Symbol & Exchange:     Nasdaq: ADZA
Investor Relations Contact:   Brandi Floberg
Investor Relations Contact Phone: 310-691-7100
Web: www.adeza.com
Date of Presentation:  November 9, 2005 at 11:15 a.m. ET

Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm(TM) The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for broad use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility.

Company:  Adherex Technologies Inc.
Ticker Symbol & Exchange:     AMEX: ADH; TSX: AHX
Investor Relations Contact:   Melissa Matson
Investor Relations Contact Phone:   919-484-8484
Web:  www.adherex.com
Date of Presentation:  Nov. 8, 2005

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin(TM)), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs.

Company:  Aksys, Ltd.
Ticker Symbol & Exchange:     AKSY - NASDAQ
Investor Relations Contact:   Larry Birch
Investor Relations Contact Phone: 847-229-2222
Web:      www.aksys.com
Date of Presentation:  November 9, 2005 - 3:30 p.m. ET

Aksys was founded to develop dialysis products and services for patients suffering from kidney failure. Our lead product, the Aksys PHD(R) System, is designed to facilitate more frequent dialysis treatments. Studies have shown that increased dialysis frequency can improve the clinical outcomes of patients, as well as reduce morbidity and the associated high cost of patient care. Aksys' approach reflects the following: more frequent treatment is better than less frequent treatment; alternate sites, such as the patient's home, are preferable locations to perform chronic therapy; and an automated, user-friendly dialysis system will make home hemodialysis the preferred alternative therapy for many patients. Improved clinical outcomes in alternate settings also enable the patient to achieve increased quality of life and rehabilitation, the original goal of government-funded ESRD programs.

Company:  Antares Pharma, Inc.
Ticker Symbol & Exchange:     AIS
Investor Relations Contact:   Steve Chizzik
Investor Relations Contact Phone:       973.912.0980
Web:      www.antarespharma.com
Date of Presentation:         11/7/05

Antares Pharma is a specialized product development company with patented drug delivery systems combined with injectable device engineering capabilities. The Company's current technology platforms include its ATD(TM) (Advanced Transdermal Delivery) system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms (Vibex(TM) disposable mini-needle injection device and Valeo(TM) and Vision(R) reusable needle-free injection devices). Antares is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company believes that its product pipeline addresses unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. The Company has active partnering programs with several pharmaceutical and distribution companies